Vident Advisory’s Novo Nordisk NVO Stock Holding History

Vident Advisory’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.02M	Buy	83,871 +46,959	+127%	+$2.02M	0.03%	464
2026 Q1	$1.36M	Sell	36,912 -4,751	-11%	-$225K	0.01%	750
2025 Q4	$2.12M	Sell	41,663 -4,960	-11%	-$254K	0.02%	561
2025 Q3	$2.59M	Sell	46,623 -3,137	-6%	-$184K	0.02%	486
2025 Q2	$3.43M	Sell	49,760 -1,386	-3%	-$94.3K	0.04%	362
2025 Q1	$3.55M	Buy	51,146 +9,685	+23%	+$800K	0.05%	310
2024 Q4	$3.57M	Sell	41,461 -1,555	-4%	-$168K	0.06%	282
2024 Q3	$5.12M	Buy	43,016 +7,049	+20%	+$940K	0.13%	153
2024 Q2	$5.13M	Buy	35,967 +4,445	+14%	+$589K	0.14%	140
2024 Q1	$4.05M	Buy	31,522 +1,258	+4%	+$150K	0.08%	244
2023 Q4	$3.13M	Sell	30,264 -447	-1%	-$44.2K	0.08%	275
2023 Q3	$2.79M	Buy	+30,711	New	+$2.71M	0.09%	244

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Vident Advisory's NVO Position: Q2 2026 in Review

Vident Advisory increased its Novo Nordisk (NVO) stake by 127% in Q2 2026, buying an estimated $2.02M and bringing the position to 83,871 shares worth $4.02M. The position accounts for 0.03% of the portfolio, ranked #464.

Vident Advisory first reported a position in NVO in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.13M in Q2 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Vident Advisory held 83,871 shares of Novo Nordisk worth $4.02M as of Q2 2026.
Vident Advisory bought 46,959 Novo Nordisk shares in Q2 2026, an estimated $2.02M.
Novo Nordisk made up 0.03% of Vident Advisory's portfolio in Q2 2026, its #464 holding.
Vident Advisory first reported a position in Novo Nordisk in Q3 2023 and has held it in 12 quarters since.
Vident Advisory's Novo Nordisk position peaked at $5.13M in Q2 2024.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.